Dr. Maya Green discusses HIV prevention, addressing racial disparities in healthcare, and the powerful impact of stigma on ...

In HIV-1-infected patients with extensive drug resistance, the optimization of background antiretroviral therapy is essential when changing drugs after treatment failure. The genotypic sensitivity ...

Cooper DA et al. Subgroup and resistance analysis of raltegravir for resistant HIV-1 infection. New England Journal of Medicine, 359: 355-365, 2008. Steigbigel RT et al. Raltegravir with optimized ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application submissions for lenacapavir for human immunodeficiency virus (HIV) prevention.

References Lalezari J et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24 week results from a phase 2b/3 ...

(CNN) — It was nearly 30 years ago when Rosember Lopez received a life-altering diagnosis: He was HIV positive. With scant government resources for HIV support at the time in Mexico, Lopez ...

The value of the 'classical' binary approaches to define genotypic sensitivity and phenotypic sensitivity scores for optimization of background HIV therapy in patients with extensive HIV drug ...